The two types of peptide users regulators keep ignoring

Here is something that does not get said plainly enough in most coverage of peptide regulation: the market is not one thing, and the people in it are not one type.

Most regulatory thinking in this space is built around a single mental model, the patient. Someone with a medical complaint, seeing a doctor, receiving a prescription, having it filled by a licensed pharmacy. That model is real and it deserves serious attention. But it describes a fraction of the people using these compounds.

There is a second population. It is large, it is not going away, and policy built without accounting for it will consistently produce worse outcomes than policy built with it in mind.

Population one: the clinical patient

This is the person the current regulatory framework is designed for. They have a health condition or concern. They see a physician. The physician evaluates them and decides that a peptide. BPC-157, TB-500, PT-141, whatever, might help. They write a prescription. A compounding pharmacy prepares the medication. The patient receives it.

This pathway has real benefits: physician oversight, quality-controlled sourcing, dosing guidance calibrated to the individual. It is the safest version of accessing these compounds, and protecting it matters. Any regulation that restricts or eliminates this pathway without replacing it with something equally or more accountable is moving backward.

Population two: the self-directed optimizer

This person has read the studies. They understand the evidence base. They have made an informed decision about their own biology. They are not sick, or they are not seeking conventional medical treatment, or they do not want to navigate the prescription system for something that is not FDA-approved. They source independently and use independently.

This population is not small. It includes biohackers, competitive athletes, longevity-focused individuals, functional health enthusiasts, and people who have been using these compounds for a decade or more with results they can describe in detail. It includes physicians using things on themselves they are not ready to prescribe. It includes people in countries where the regulatory framework is different. It is a real and substantial market.

And it is almost entirely invisible in regulatory discussions.

Why the gap matters

When regulation is designed only for population one, here is what happens to population two: nothing changes except the quality of their sourcing options.

If compounding pharmacies are restricted from preparing BPC-157, the self-directed optimizer does not get a prescription and do it "the right way." They do not stop. They source from the gray market. The research chemical supply chain. The channels with the least oversight and the most contamination risk.

The net outcome: the safest, most accountable sourcing pathway gets restricted, and the volume moves to less accountable channels. That is not harm reduction. That is harm displacement.

What regulation that works for both would look like

I am not arguing against regulation. I am arguing for regulation that accounts for the actual market. Here is what that looks like:

• Protect the compounding pathway for compounds with legitimate clinical applications and physician oversight. Restricting it without providing an alternative just removes the accountability without removing the use.
• Build a quality floor for the gray market. Minimum testing standards, COA requirements, traceability mandates. The infrastructure to do this already exists among reputable suppliers. Make it the floor, not just a differentiator.
• Distinguish between access restriction and safety improvement. These are not the same thing. A rule that restricts access while doing nothing to improve the quality or safety of the market that persists anyway is not a safety rule, it is a restriction for its own sake.
• Include the self-directed population in the conversation. They are the majority of users. Building policy without them is building incomplete policy.

The honest version of this argument

The peptide community has a bad habit of framing every regulatory move as an attack to be resisted. That framing is not only wrong, it is counterproductive. It signals that the community is not serious about safety, which makes regulators less likely to engage seriously with nuanced arguments.

The honest version is this: real risks exist in this market, concentrated at the unaccountable end of the supply chain. The right response is regulation that addresses those risks directly, quality standards, traceability, contamination testing. What does not help is restriction of the cleanest parts of the market paired with no action on the parts that are actually dangerous.

Both populations, the clinical patient and the self-directed optimizer, deserve a market with a quality floor. The current moment is an opportunity to build one. Whether the regulatory process takes it seriously enough to try is a different question.

Questions I get asked